Share on StockTwits

Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Peter Mueller unloaded 7,500 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $61.63, for a total transaction of $462,225.00. Following the transaction, the executive vice president now directly owns 158,750 shares of the company’s stock, valued at approximately $9,783,763. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on VRTX shares. Analysts at Maxim Group raised their price target on shares of Vertex Pharmaceuticals from $88.00 to $92.00 in a research note on Monday, February 24th. They now have a “buy” rating on the stock. Analysts at TheStreet upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $94.00.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 0.34% on Thursday, hitting $64.17. The stock had a trading volume of 1,387,435 shares. Vertex Pharmaceuticals has a 52 week low of $51.96 and a 52 week high of $89.96. The stock has a 50-day moving average of $73.63 and a 200-day moving average of $73.58. The company’s market cap is $15.129 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, January 29th. The company reported ($0.56) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.49) by $0.07. The company had revenue of $351.20 million for the quarter, compared to the consensus estimate of $221.08 million. During the same quarter last year, the company posted ($0.35) earnings per share. Vertex Pharmaceuticals’s revenue was up 5.1% compared to the same quarter last year. On average, analysts predict that Vertex Pharmaceuticals will post $-2.24 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.